pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene is a pharma organization headquartered in Camana Bay, KY. Primary therapeutic focus areas include Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19, Ovarian Cancer, Carcinoma, Hepatoce
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
Surzebiclimab
Phase 2 · small molecule · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
Surzebiclimab for Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in is a Phase 2 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Internal code BGB-900-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BeiGene
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
- Status
- completed
- Trials
- 1